<DOC>
	<DOC>NCT00622505</DOC>
	<brief_summary>This study will evaluate the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma patients who have been on an IV bisphosphonate for about one to two years.</brief_summary>
	<brief_title>Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Confirmed diagnosis of multiple myeloma Have been on zoledronic acid or pamidronate for 12 years and therapy must have been initiated for osteolytic lesion, bone fracture, spinal compression or osteopenia due to multiple myeloma Stable renal function Known sensitivity to bisphosphonates Receiving investigational drugs considered not safe for coadministration or have significant effect on bone turnover Current active dental problems Had bone marrow transplant or blood stem cell transplant within 2 months before study entry or planned transplant within 2 months following enrollment Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>skeletal complications</keyword>
	<keyword>bone</keyword>
</DOC>